Zydus will enter a competitive field, with an FDA decision on CymaBay's PBC drug due in August. Gilead Sciences announced its acquisition of CymaBay for $4.3 billion earlier in February. Saroglitazar, currently in a mid-to-late-stage trial for PBC, is also being tested for Metabolic Dysfunction-Associated Steatohepatitis (MASH), a type of fatty liver disease."